Will the FDA approve retatrutide? (retatrutide (LY3437943))
Dec 9, 2027even chance by
- Before Jan 1, 20272%
- Before Jul 1, 202712%▼ 9
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
Install
When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
The odds
98%before December
- before December98%▲ 6
- before 202798%▲ 5
- before April 202798%
How the odds have moved
before December: 59% on Oct 20, 98% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Why it moved
- Nov 4, 11 PM ETbefore December: 34% → 84%
No headline about it in the hours around this move.
- Nov 2, 10 PM ETbefore December: 24% → 16%
No headline about it in the hours around this move.
- Oct 21, 5 PM ETbefore December: 49% → 41%
No headline about it in the hours around this move.
The biggest swings over the chart's period, each with the headlines about the market's subject published in the hours before it. News and odds moving together is not proof one caused the other.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| before December | 98% | ▲ 6 | 96¢ | $1.02 | 10.8K | |
| before 2027 | 98% | ▲ 5 | 96¢ | $1.02 | 2.0K | |
| before April 2027 | 98% | 96¢ | 99¢ | $1.01 | 939 | |
| before September | 3% | $33.33 | 7.0K | |||
| before October | 2% | $50.00 | 9.3K | |||
| before November | 1% | ▼ 1 | $100.00 | 7.8K |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: Compass Pathways, COMP360
Search ›- Compass Pathways Remains on Track for COMP360 Launch Following Q3 Results, RBC SaysCompass Pathways reported Q3 results, with near-term catalysts for its targeted H1 2027 COMP360 launch remaining on track, RBC Capital Markets said in a note Tuesday. The company expects to submit... Biotechnology & Medical Research…
- Transcript : COMPASS Pathways plc, Q3 2026 Earnings Call, Nov 03, 2026Presentation Operator MessageOperator Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Third Quarter 2026 Conference Call. [Operator Instructions] As a reminder, this call is Transcript : COMPASS Pathways plc, Q3 2026…
- Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11thPublished on 11/04/2026 at 06:31 am EST Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Stifel…
- Compass Pathways PLC Sponsored ADR $CMPS Stock Acquired by Sumitomo Mitsui Trust Group Inc.Posted by Michael Walen on Nov 7th, 2026 Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the…
- Compass Pathways Q3 Earnings Call HighlightsPosted by Sarita Garza on Nov 4th, 2026 Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within…
- COMPASS Pathways - American Depository Shares Stock 12‑Month Price Target Cut to $23.18, Implies 176% UpsideTradingView COMPASS Pathways - American Depository Shares Stock 12‑Month Price Target Cut to $23.18, Implies 176% Upside - According to estimates from 17 analysts, COMPASS Pathways Plc - American Depository Shares stock's average price…
- COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call TranscriptCOMPASS Pathways plc (CMPS) Q3 2026 Earnings Call November 3, 2026 8:00 AM ESTCompany ParticipantsStephen Schultz - Senior Vice President of Investor... COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Stephen…
- Compass Pathways: 3 Key Takeaways for Long-Term InvestorsIts clinic network of more than 8,500 interventional psychiatry centers gives COMP360 a ready path to patients once approved. COMPASS is preparing for the potential commercial launch of COMP360 by leveraging existing interventional…
- Exclusive BAC Article: Compass Pathways; NDA Submission COMP360 TRD Next 2-Weeks, Launch 1st Half 2027, Competitor Filing MDD Underway, PTSD Expansion And CatalystsI believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Compass Pathways (CMPS). | Biotech Analysis Central Exclusive BAC Article: Compass Pathways; NDA Submission COMP360 TRD Next 2-Weeks…
- COMPASS Pathways ADS GAAP EPS of -$0.31 beats by $0.10Compass Pathways Q3 earnings beat estimates as cash jumps to $444M. - COMPASS Pathways ADS press release (CMPS): Q3 GAAP EPS of -$0.31 beats by $0.10. - Cash and cash equivalents were $444.0 million as of September 30, 2026, compared with…
- Compass Pathways reports US$444M cash and runway into 2028The psilocybin developer expects its final application submission within two weeks, with a launch targeted for the first half of 2027. Cash is expected to fund operations into 2028 as Compass Pathways plc NASDAQCMPS reported US$444 million…
- COMPASS Pathways rebounds on earnings after selloff driven by rival’s NDA submissionCompass Pathways (CMPS) stock rebounds after Q3 results calm launch fears over psilocybin compound COMP360 as Usona completes FDA filings first. Read more here. Yarygin/iStock via Getty Images Following a sharp selloff in the previous…
Related markets
All fda & drugs ›Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
16%chance▼ 1
When will the FDA reclassify BPC-157 to Category 1?
10%Before 2027
- Before 202710%▲ 1
When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
90%Before 2028
- Before 202890%▼ 1
- Before October 202788%▼ 1
- Before July 202787%
2 more
- Before Mar 1, 202765%▼ 1
- Before Jan 1, 202719%▲ 2
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
74%chance▼ 1
When will Beam Therapeutics submit a BLA for Risto-cel?
93%before April 2027
- before April 202793%▲ 15
- before 202756%▼ 1
- before December14%
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues just now. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions